Latest Patent Applications News

Anson Resources has lodged two US patent applications for a novel chemical-free technology that removes iron from lithium-rich brines, potentially cutting costs and environmental impact in its Direct Lithium Extraction process.

Senetas Corporation reported a 4.7% rise in revenue to $20.2 million for FY2026, achieving a strong $4.4 million operating cash flow turnaround. The company advanced its AI governance platform while maintaining a robust sales pipeline and capital management strategy.

Zeotech Limited’s zeoteCH4® technology slashed methane emissions by an average 92% in a six-month landfill trial at North Burnett Regional Council, confirming its promise as a practical methane mitigation solution under real-world conditions.

AdAlta Limited (ASX:1AD) has progressed its ‘East to West’ cellular immunotherapy strategy by securing its first CAR-T asset, advancing Australian manufacturing and US FDA regulatory engagement, while raising A$5.3 million in FY2026 and reporting a net loss of $4.68 million.

Mount Ridley Mines has lodged a provisional patent for its SelectroTM hydrometallurgical leach technology, demonstrating superior recoveries of rare earths, scandium, and gallium compared to conventional methods. The company is advancing testwork and commercial discussions to capitalise on the innovation.

ION Video has appointed two seasoned executives to its board and elevated Anthony Baker to Managing Director as it sharpens focus on scaling its patented video technology. Founder Finbar O’Hanlon steps back from the board to concentrate on innovation and expanding the company’s IP portfolio.

Proteomics International has achieved a key patent acceptance in Australia for its PromarkerEndo blood test, reinforcing its intellectual property portfolio and commercialisation strategy in a major healthcare market.

InFocus Group Holdings has rolled out a major upgrade to its Codexa sweepstakes casino platform, introducing a VIP-style player experience and a proprietary AI-driven compliance engine designed to streamline operations and reduce costs for white-label operators.

EVE Health Group has progressed its Libbo pilot clinical study for erectile dysfunction with dosing set for Q4 2026 and achieved a major solubility breakthrough for apixaban, while appointing Ben Rohr as CEO to drive commercial growth.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.

Amplia Therapeutics reported encouraging mature data from its ACCENT trial, initiated a Phase 2b pancreatic cancer study, launched an ovarian cancer trial, and refreshed its board leadership while maintaining a solid cash balance of A$24 million.